|
|
|
|
This Web site is supported by educational grants from Genentech BioOncology, GlaxoSmithKline, and Pfizer Oncology. |
|
|
|
|
| |
 |
|
|
|
|
|
|
|
Home |
 |
|
| News Updates! |
The appearance of news releases and external hyperlinks does not constitute endorsement by PER of the news release; linked Web sites; or information, products, or positions contained therein. |
UPDATE 1-EU body warns on anaemia drugs in cancer patients
| Dose of reality: health services curb drug costs
| A.P. Pharma fills up clinical trial of nausea drug
| FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
| BioGeneriX and Neose Technologies Initiate Phase 2 Trial for GlycoPEG-GCSF
| June 23, 2008, 3:02 PM | MSN |
| Glaxo gets formal EU okay for breast cancer drug
|
Read More >> |
| Journal Watch Updates! |
| In a phase II trial of patients with refractory metastatic breast cancer, lapatinib demonstrated modest activity and a manageable toxicity profile in patients with HER2+ disease, while HER2- patients did not appear to benefit. | | June 20, 2008, 6:05 PM | Ann Oncol | PubMed |
|
| Expression of the apoptosis-related protein Bcl-2 was significantly associated with ipsilateral breast tumor recurrence and serves as an independent prognostic factor for breast recurrence in patients with early stage breast cancer. | | June 20, 2008, 6:04 PM | Breast Cancer Res Treat | PubMed |
|
| Patients with ER+ MBC with elevated serum levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) demonstrated significantly reduced tumor response, time to progression, and overall survival with either tamoxifen or letrozole therapy compared to patients with normal serum levels of TIMP-1. | | June 20, 2008, 6:04 PM | J Clin Oncol | PubMed |
|
| Expression of matrix-metalloproteinase-like enzyme ADAM17 was significantly higher in high-grade compared to low-grade invasive breast tumors and high ADAM17 expression was significantly associated with shorter overall survival in patients with invasive breast cancer. | | June 20, 2008, 6:03 PM | Ann Oncol | PubMed |
|
Read More >> |
|
Journals
|
 |
Clinical Breast Cancer
December 2007
(Vol. 7 No. 11)
Table of Contents |
|
Interactive Case Studies
|
 |
1 AMA PRA Category 1 Credit™
Expiration date: December 28, 2008 |
| Interactive Case Study: Treatment Options for a Patient With Metastatic Breast Cancer Who Cannot Receive a Conventional Taxane
|
|
Interviews with Key Opinion Leaders
|
 |
Medical Director, US Oncology Research, Houston, TX |
| Watch Video |
|
 |
Professor of Oncology, Université Libre de Bruxelles, Department Head, Medicine, Jules Bordet Institute, Belgium |
| Watch Video |
|
 |
Professor of Medical Statistics & Epidemiology, University of Oxford Oxford, United Kingdom |
| Watch Video |
|
|
|
|
| What's
New Online! |
 |
Vol. 5, No. 1
1 AMA PRA Category
1 Credit™
Expiration date: June 6, 2009 |
 |
|
 |
April 2008
1 AMA
PRA Category 1 Credit™
Expiration date: June 4, 2009
|
 |
April 2008
2 AMA PRA Category
1 Credits™
Expiration date: June 4, 2009 |
|
|
|
|
|
